Compound Evidence File
#EC-2026-0768
Survodutide
Filed under Peptides. The bureau holds 60 laboratory returns for this compound from 13 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
13 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 5 | 10.0 | 10.0 | 10.0 | 23 May 2026 | 23 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 8.9 | 7.7 | 9.8 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.6 | 7.1 | 10.0 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 5 | 8.6 | 8.1 | 9.3 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 4 | 8.5 | 8.1 | 9.2 | 25 May 2026 | 25 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 8 | 8.4 | 7.5 | 9.7 | 24 May 2026 | 24 May 2026 |
| Peptide-SCASE #VI-2026-0111 | A | 4 | 7.5 | 6.5 | 9.0 | 16 Jul 2025 | 25 Nov 2025 |
| Polaris PeptidesCASE #VI-2026-0839 | B | 5 | 7.3 | 5.9 | 8.8 | 25 Apr 2025 | 12 Aug 2025 |
| Qing Li PeptideCASE #VI-2026-0469 | A | 3 | 7.2 | 6.8 | 7.4 | 14 Jul 2025 | 3 Oct 2025 |
| Skye PeptidesCASE #VI-2026-0451 | B | 4 | 6.8 | 6.1 | 7.3 | 6 May 2025 | 21 May 2025 |
| UtherCASE #VI-2026-0902 | D | 3 | 6.5 | 3.7 | 8.6 | 9 Oct 2025 | 23 Oct 2025 |
| Paramount PeptidesCASE #VI-2026-0550 | C | 3 | 5.2 | 4.6 | 6.0 | 25 Apr 2025 | 6 May 2025 |
Open any subject to view the batch-level evidence for Survodutide alone.